P Vijendran1, R Verma2, N Hazra3, B Vasudevan4, M Debdeep5, V Ruby6, N Shekar7. 1. Classified Specialist (Dermatology and Venereology), Base Hospital, Lucknow 226002, India. 2. Commandant, Base Hospital, Lucknow 226002, India. 3. Senior Advisor (Microbiology), Command Hospital (Central Command), Lucknow 226002, India. 4. Senior Advisor (Dermatology and Venereology), Base Hospital, Lucknow 226002, India. 5. Graded Specialist (Dermatology and Venereology), Base Hospital, Delhi, India. 6. Graded Specialist (Dermatology and Venereology), Command Hospital (Southern Command), Pune 411040, India. 7. Graded Specialist (Dermatology and Venereology), Command Hospital (Eastern Command), Kolkata 700021, India.
Abstract
BACKGROUND: Dermatological diseases are the first recognized clinical manifestation Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS).1, 2 The present study was undertaken to find out the clinical spectrum of the superficial mycoses, the etiological organisms and their drug sensitivity patterns among HIV positive patients and non HIV individuals attending the tertiary care hospital. METHODS: The study population was 100 HIV patients and control patients were consecutive 100 HIV negative patients. Skin scrapings and swabs were obtained from the upper back, web spaces of toes, inguinal region, dorsum of tongue. All the samples were subjected to potassium hydroxide mount and stained with Calcoflour White and were cultured. The fungi were identified on the basis of colony and microscopic features in conjunction with results of physiologic evaluation by standard phenotypic identification criteria. RESULTS: The total number of seropositive patients who had atleast one fungal infection was 57 and the total number of seronegative patients who had atleast one fungal infection was 21. In our study, fungal colonization was seen in 3.6% in clinically normal sites in retropositive patients and 1.6% in retronegatives. 76.59% in retropositive and 85.71% in retronegative patients the fungi cultured were sensitive to fluconazole. CONCLUSION: The findings of this study suggest that the skin of HIV patients may more frequently harbour common fungi even in the absence of visible clinical signs. Antifungal-resistant fungi should be kept in mind while treating fungal infections.
BACKGROUND: Dermatological diseases are the first recognized clinical manifestation Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS).1, 2 The present study was undertaken to find out the clinical spectrum of the superficial mycoses, the etiological organisms and their drug sensitivity patterns among HIV positive patients and non HIV individuals attending the tertiary care hospital. METHODS: The study population was 100 HIV patients and control patients were consecutive 100 HIV negative patients. Skin scrapings and swabs were obtained from the upper back, web spaces of toes, inguinal region, dorsum of tongue. All the samples were subjected to potassium hydroxide mount and stained with Calcoflour White and were cultured. The fungi were identified on the basis of colony and microscopic features in conjunction with results of physiologic evaluation by standard phenotypic identification criteria. RESULTS: The total number of seropositive patients who had atleast one fungal infection was 57 and the total number of seronegative patients who had atleast one fungal infection was 21. In our study, fungal colonization was seen in 3.6% in clinically normal sites in retropositive patients and 1.6% in retronegatives. 76.59% in retropositive and 85.71% in retronegative patients the fungi cultured were sensitive to fluconazole. CONCLUSION: The findings of this study suggest that the skin of HIV patients may more frequently harbour common fungi even in the absence of visible clinical signs. Antifungal-resistant fungi should be kept in mind while treating fungal infections.
Authors: H K Kar; R Narayan; R K Gautam; R K Jain; V Doda; D Sengupta; N C Bhargava Journal: Indian J Dermatol Venereol Leprol Date: 1996 Sep-Oct Impact factor: 2.545
Authors: P K Kaviarasan; T J Jaisankar; Devinder Mohan Thappa; S Sujatha Journal: Indian J Dermatol Venereol Leprol Date: 2002 Jul-Aug Impact factor: 2.545
Authors: Robert B Ashman; Camile S Farah; Siripen Wanasaengsakul; Yan Hu; Gerald Pang; Robert L Clancy Journal: Immunol Cell Biol Date: 2004-04 Impact factor: 5.126
Authors: M López-Dupla; P Mora Sanz; V Pintado García; E Valencia Ortega; P L Uriol; M A Khamashta; A G Aguado Journal: Am J Gastroenterol Date: 1992-12 Impact factor: 10.864
Authors: Camila Stofella Sodré; Paulo Matheus Guerra Rodrigues; Mayra Stambovsky Vieira; Alexandre Marques Paes da Silva; Lucio Souza Gonçalves; Marcia Gonçalves Ribeiro; Dennis de Carvalho Ferreira Journal: J Oral Microbiol Date: 2020-08-17 Impact factor: 5.474